CalciMedica Shares Scheduled to Reverse Split on Monday, August 31st (NASDAQ:CALC)

CalciMedica Inc. (NASDAQ:CALC)’s stock is set to reverse split on Monday, August 31st. The 1-5 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 30th.

CalciMedica Trading Down 20.0%

CALC stock traded down $0.12 during mid-day trading on Thursday, reaching $0.47. 1,490,454 shares of the stock traded hands, compared to its average volume of 1,026,720. CalciMedica has a one year low of $0.46 and a one year high of $7.20. The stock has a market capitalization of $16.05 million, a PE ratio of -0.35 and a beta of 0.91. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. The business has a 50-day moving average price of $0.76 and a two-hundred day moving average price of $0.70.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.17). Equities research analysts expect that CalciMedica will post -1.05 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on CALC shares. Guggenheim started coverage on shares of CalciMedica in a report on Thursday, August 20th. They issued a “buy” rating for the company. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Wall Street Zen raised shares of CalciMedica to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings downgraded shares of CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Finally, UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.00.

Insider Activity at CalciMedica

In other CalciMedica news, Director Fred A. Middleton acquired 248,972 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were acquired at an average cost of $0.80 per share, with a total value of $199,177.60. Following the acquisition, the director directly owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. The trade was a 30.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 28.25% of the stock is owned by company insiders.

Hedge Funds Weigh In On CalciMedica

Several institutional investors and hedge funds have recently modified their holdings of CALC. Renaissance Technologies LLC increased its stake in shares of CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after purchasing an additional 39,775 shares in the last quarter. 180 Wealth Advisors LLC increased its stake in shares of CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of CalciMedica during the fourth quarter valued at approximately $506,000. Finally, PVG Asset Management Corp acquired a new stake in shares of CalciMedica in the fourth quarter worth approximately $302,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.